Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Hypothalamo-pituitary-adrenal axis, glucose metabolism and TNF-α in narcolepsy

E. Maurovich-Horvat, M. Keckeis, Z. Lattová, D. Kemlink, TC. Wetter, A. Schuld, K. Sonka, T. Pollmächer,

. 2014 ; 23 (4) : 425-431.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT13238 MZ0 CEP Register

Narcolepsy with cataplexy is caused by a deficiency in the production of hypocretin/orexin, which regulates sleep and wakefulness, and also influences appetite, neuroendocrine functions and metabolism. In this case-control study, 11 patients with narcolepsy with cataplexy and 11 healthy adults underwent an oral glucose tolerance test, and dexamethasone suppression/corticotropin-releasing hormone stimulation test. The average age of patients and controls was 35.1 ± 13.2 and 41.0 ± 2.9 years, respectively, body mass index was 28.1 ± 6.6 and 25.5 ± 4.7 kg m(-2) . We did not find evidence of a significantly increased prevalence of disturbed glucose tolerance in patients with narcolepsy. After hypothalamo-pituitary-adrenal axis suppression, the number of non-suppressors did not differ between the groups, indicating normal negative feedback sensitivity. The level of cortisol after dexamethasone suppression was significantly lower in patients with narcolepsy, suggesting a slight basal downregulation and/or a slightly increased negative feedback sensitivity of the major endocrine stress system in narcolepsy. Following corticotropin-releasing hormone stimulation, there were no significant differences in levels of adrenocorticotropic hormone or cortisol, and in adrenocortical responsivity to adrenocorticotropic hormone. Finally, patients with narcolepsy displayed significantly higher plasma levels of tumour necrosis factor alpha, soluble tumour necrosis factor receptor p55, soluble tumour necrosis factor receptor p75 and interleukin 6 after adjustment for body mass index. The present study confirms that narcolepsy by itself is not associated with disturbances of glucose metabolism, but goes along with a subtle dysregulation of inflammatory cytokine production. We also found that dynamic hypothalamo-pituitary-adrenal system response is not altered, whereas negative feedback to dexamethasone might be slightly enhanced.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008176
003      
CZ-PrNML
005      
20181023090844.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jsr.12138 $2 doi
035    __
$a (PubMed)24650212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Maurovich Horvat, Eszter $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic; Centre of Mental Health, Klinikum Ingolstadt, Ingolstadt, Germany; Max Planck Institute of Psychiatry, Munich, Germany. $7 xx0208396
245    10
$a Hypothalamo-pituitary-adrenal axis, glucose metabolism and TNF-α in narcolepsy / $c E. Maurovich-Horvat, M. Keckeis, Z. Lattová, D. Kemlink, TC. Wetter, A. Schuld, K. Sonka, T. Pollmächer,
520    9_
$a Narcolepsy with cataplexy is caused by a deficiency in the production of hypocretin/orexin, which regulates sleep and wakefulness, and also influences appetite, neuroendocrine functions and metabolism. In this case-control study, 11 patients with narcolepsy with cataplexy and 11 healthy adults underwent an oral glucose tolerance test, and dexamethasone suppression/corticotropin-releasing hormone stimulation test. The average age of patients and controls was 35.1 ± 13.2 and 41.0 ± 2.9 years, respectively, body mass index was 28.1 ± 6.6 and 25.5 ± 4.7 kg m(-2) . We did not find evidence of a significantly increased prevalence of disturbed glucose tolerance in patients with narcolepsy. After hypothalamo-pituitary-adrenal axis suppression, the number of non-suppressors did not differ between the groups, indicating normal negative feedback sensitivity. The level of cortisol after dexamethasone suppression was significantly lower in patients with narcolepsy, suggesting a slight basal downregulation and/or a slightly increased negative feedback sensitivity of the major endocrine stress system in narcolepsy. Following corticotropin-releasing hormone stimulation, there were no significant differences in levels of adrenocorticotropic hormone or cortisol, and in adrenocortical responsivity to adrenocorticotropic hormone. Finally, patients with narcolepsy displayed significantly higher plasma levels of tumour necrosis factor alpha, soluble tumour necrosis factor receptor p55, soluble tumour necrosis factor receptor p75 and interleukin 6 after adjustment for body mass index. The present study confirms that narcolepsy by itself is not associated with disturbances of glucose metabolism, but goes along with a subtle dysregulation of inflammatory cytokine production. We also found that dynamic hypothalamo-pituitary-adrenal system response is not altered, whereas negative feedback to dexamethasone might be slightly enhanced.
650    _2
$a adrenokortikotropní hormon $x krev $7 D000324
650    _2
$a dospělí $7 D000328
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kataplexie $x krev $x komplikace $x metabolismus $7 D002385
650    _2
$a hormon uvolňující kortikotropin $x farmakologie $7 D003346
650    _2
$a dexamethason $x farmakologie $7 D003907
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukózový toleranční test $7 D005951
650    _2
$a lidé $7 D006801
650    _2
$a hydrokortison $x krev $7 D006854
650    _2
$a systém hypotalamus-hypofýza $x účinky léků $x metabolismus $7 D007030
650    _2
$a interleukin-6 $x metabolismus $7 D015850
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a narkolepsie $x krev $x komplikace $x metabolismus $7 D009290
650    _2
$a systém hypofýza - nadledviny $x účinky léků $x metabolismus $7 D010913
650    _2
$a TNF-alfa $x krev $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Keckeis, Marietta
700    1_
$a Lattová, Zuzana $7 xx0070969
700    1_
$a Kemlink, David $7 xx0081396
700    1_
$a Wetter, Thomas-Christian
700    1_
$a Schuld, Andreas
700    1_
$a Šonka, Karel, $d 1957- $7 jn99240001644
700    1_
$a Pollmächer, Thomas
773    0_
$w MED00002940 $t Journal of sleep research $x 1365-2869 $g Roč. 23, č. 4 (2014), s. 425-431
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24650212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20181023091351 $b ABA008
999    __
$a ok $b bmc $g 1065449 $s 890976
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 23 $c 4 $d 425-431 $i 1365-2869 $m Journal of sleep research $n J Sleep Res $x MED00002940
GRA    __
$a NT13238 $p MZ0
LZP    __
$a Pubmed-20150306

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...